Industry

With the launch of its newest MoneyGuard solution, Lincoln Financial continues to demonstrate its commitment to the hybrid long-term care space. RADNOR, Pa.–(BUSINESS WIRE)–Lincoln Financial Group (NYSE: LNC) is meeting shifting customer preferences for growth over guarantees1 with the launch of Lincoln MoneyGuard Market Advantage® (2024), issued by The Lincoln National Life Insurance Company, Fort … [Read more…]

Highlights Optiscan signs Know-How agreement with US-based Mayo Clinic to develop new endomicroscopic imaging system The companies will work together to co-develop technology for use in robotic surgery Co-development and clinical testing will commence with initial focus on robotic-assisted breast cancer surgery Mayo Clinic will take a financial interest in Optiscan’s technology MELBOURNE, Australia–(BUSINESS WIRE)–Optiscan … [Read more…]

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene amplifications First patient dosed in Phase 1/2 STARMAP clinical trial of BBI-825 in patients with tumors with resistance gene amplifications Completed $100 million IPO; pro forma cash position of approximately $200 million supports both BBI-355 … [Read more…]

Lead Candidate SAP-021 to be Developed on 505(b)(2) FDA Regulatory Pathway Based on Phase 1 Results Demonstrating Bioavailability in Comparison to Epidiolex® Patent Protected Production Technology Allows for Scalable Manufacturing of Orally Administered Capsules to Address Large Patient Populations Led by Highly Relevant Leadership Team with Deep Understanding of Cannabinoid Pharmaceutical Drug Development LONDON & … [Read more…]

The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ … [Read more…]

– PDE9 inhibitor, CRD-740, demonstrated favorable safety profile and achieved statistical significance for the trial’s primary endpoint, median increase in plasma cyclic guanosine monophosphate (cGMP) – – This clinical trial confirms that high levels of PDE9 inhibition lead to increases in cGMP, reflecting increased activation of the myocardial natriuretic peptide (NP) signaling pathway – – … [Read more…]

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units (RSUs) of the company’s common stock to 14 … [Read more…]

Engineering of X-Editors (XE), Scribe’s proprietary genome editing platform, for potency and specificity enables XE to become the first non-Cas9-based molecule to achieve saturating levels of editing in the NHP liver (exceeding 75% whole liver editing) without any detectable off-targets Data also highlight the ability of XE to achieve safe and saturated levels of editing … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “PEGylated Proteins Market 2023-2028” report has been added to ResearchAndMarkets.com’s offering. The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and is projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 … [Read more…]

New Cardiovascular Age and Cardio Capacity capabilities further establish ŌURA as a personal health companion for improving healthspan and longevity SAN FRANCISCO–(BUSINESS WIRE)–ŌURA, maker of Oura Ring, the most accurate and trusted smart ring, announced the launch of two new heart health features: Cardiovascular Age (CVA) and Cardio Capacity. The two product advancements signal the … [Read more…]